Clinical trials: in Mauritius
Healthy, Melasma (Facial Melasma)
COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS
The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with…
- Conditions
- Healthy, Melasma (Facial Melasma), Epidermal Melasma
- Trial name
- NCT07071363
- Testing
- Depigmenting Cosmetic Serum (Applied Morning and Evening)
- Where
- Mauritius
- Volunteers
- 40 people
- Sponsor
- Laboratoire Dermatologique ACM
Rheumatoid Arthritis
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study.
- Trial name
- SPECIFI-RA (NCT06073093)
- Testing
- SAR441566
- Where
- 102 sites in United States, Argentina and 17 more
- Volunteers
- 264 people
- Sponsor
- Sanofi
Acne, Post-inflammatory Hyperpigmentation
Clinical Efficacy of the Product in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP) Subjects
Double-blind, randomized, clinical study is designed to evaluate the efficacy of Niacinamide A in the management of facial Post Inflammatory Hyper Pigmentation (PIHP) in healthy female and male subjects with moderate to severe…
- Trial name
- NCT06822335
- Where
- Mauritius
- Volunteers
- 65 people
- Sponsor
- Cosmetique Active International
Acne, Postinflammatory Hyperpigmentation
Efficacy of La Roche Posay Routine in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP)
The goal of this clinical trial is to test and compare La Roche Posay routine --the studied product-- with a comparator product in participants with acne.
- Trial name
- PIHP (NCT06770127)
- Where
- Mauritius
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Head Lice Infestation
Comparative Study for the Evaluation of Two Medical Devices on the Treatment of Head Lice Infestation
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice).
- Trial name
- NCT06057506
- Testing
- Paranix® Lotion
- Where
- Mauritius
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b Study in NASH to Assess IVA337
Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common.
- Trial name
- NATIVE (NCT03008070)
- Testing
- IVA337
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 247 people
- Sponsor
- Inventiva Pharma
Skin Diseases
Evaluation of Cicaplast in Subjects With Skin Irritation
The aim of this open, before/after, multicentric study is to assess the effect and tolerance of Cicaplast Baume B5 in patients having a skin irritation (irritative and cracked dermatitis, dry eczematids, rubbing irritation, ...)…
- Trial name
- NCT05767333
- Where
- 4 sites in United States, China and 2 more
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis
In this study, we will test the tolerance of a topical product and its efficacy in reducing the atopy crisis duration and severity.
- Trial name
- NCT05531188
- Where
- Mauritius
- Volunteers
- 68 people
- Sponsor
- Cosmetique Active International
Acne
Cutaneous Acceptability, Comedogenic Potential and Efficacy of Two Cosmetic Products Used in Synergy
The open, intra-individual study aims to assess the cutaneous acceptability, comedogenic potential and efficacy of a cleansing gel and a cream used in synergy to relieve patients presenting with acne grade 2 and 3.
- Trial name
- NCT05490537
- Where
- 2 sites in Mauritius, Poland
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Head Lice
Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice).
- Trial name
- NCT05379114
- Testing
- INVESTIGATIONAL DEVICE, Comparator device
- Where
- Mauritius
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Type 2 Diabetes Mellitus
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Primary Objective: To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as compared to placebo in pediatric patients with T2DM.
- Trial name
- NCT02803918
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 11 sites in United States, Mauritius and 4 more
- Volunteers
- 23 people
- Sponsor
- Sanofi
Vulvovaginal Candidiasis, Genital
Effect of Ultra-gyn® on Vulvovaginal Candidiasis
The aim of this post-market clinical follow up study is to confirm the performance and the safety of Ultra-gyn® (when used in accordance with its approved labelling)
- Trial name
- NCT05273333
- Testing
- Ultra-gyn®
- Where
- Mauritius
- Volunteers
- 30 people
- Sponsor
- Biocodex
Systemic Lupus Erythematosus
A Phase II Study of M2951 in SLE
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus…
- Trial name
- NCT02975336
- Testing
- M2951
- Where
- 157 sites in United States, Argentina and 17 more
- Volunteers
- 469 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Acne Vulgaris
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
This is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with moderate to severe acne vulgaris on the face.
- Trial name
- EDeN (NCT02932267)
- Testing
- Adapalene 0.3% / BPO 2.5% gel
- Where
- 3 sites in United States, Mauritius and 1 more
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Hepatitis C, Hepatitis C, Chronic
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection
- Trial name
- NCT04019717
- Testing
- AT-527, Daclatasvir
- Where
- 3 sites in Belgium, Mauritius and 1 more
- Volunteers
- 10 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Sunburn
Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn
A phase II multicenter, double-blinded clinical trial of the safety and efficacy of SP160412 in the temporary relief of mild to moderate, (i.e. first degree) sunburn
- Trial name
- NCT03332524
- Testing
- SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg
- Where
- Mauritius
- Volunteers
- 80 people
- Sponsor
- Sephoris Pharmaceuticals LLC
Chronic Hepatitis C
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC)…
- Trial name
- NCT02569710
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- 11 sites in Mauritius, Moldova and 2 more
- Volunteers
- 161 people
- Sponsor
- Alios Biopharma Inc.
Lupus Erythematosus, Systemic
Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main…
- Trial name
- IP-006 (NCT03427151)
- Testing
- IPP-201101
- Where
- 14 sites in United States, Czechia and 5 more
- Volunteers
- 62 people
- Sponsor
- ImmuPharma
Lupus Erythematosus, Systemic
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
This current Phase 3 study will evaluate the efficacy and safety of administration of subcutaneous (sc) IPP-201101 in patients with active SLE.
- Trial name
- LUPUZOR (NCT02504645)
- Testing
- IPP-201101, Standard of Care
- Where
- 30 sites in United States, Czechia and 6 more
- Volunteers
- 202 people
- Sponsor
- ImmuPharma
Systemic Lupus Erythematosus
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy and safety of ILT-101 (human recombinant interleukin 2 (IL-2)) in patients with moderate to severe systemic lupus erythematosus.
- Trial name
- LUPIL-2 (NCT02955615)
- Testing
- ILT-101
- Where
- 25 sites in Austria, Bulgaria and 8 more
- Volunteers
- 100 people
- Sponsor
- Iltoo Pharma